We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
There comes the second FDA-approved biosimilar of AbbVie’s branded drug Humira (adalimumab), as the tumor necrosis factor (TNF) blocker Cyltezo of Boehringer Ingelheim was approved for marketing by FDA on August 25.